I agree that the issue is marketablility. I keep recalling the enthusiasm of the Elis press release two weeks ago.
"Because of Elis' proven marketing strategies and the patient responses we've already experienced as part of our sampling program, we anticipate strong sales of Vitaros(R) in this region, where the total market for erectile dysfunction drugs is more than $100 million per year," continued Mr. Assouma.
That kind of endorsement based on their own samling program is comforting. Further, approval for this area of the middle east appears to be relying on the Canadian approval and is "expected" in 2012.
Having said that, the pps is barely above its close yesterday.
News 
Market Data 
Discover 
